JP2015155400A - Composition for transplantation containing corneal endothelial cell - Google Patents
Composition for transplantation containing corneal endothelial cell Download PDFInfo
- Publication number
- JP2015155400A JP2015155400A JP2015005492A JP2015005492A JP2015155400A JP 2015155400 A JP2015155400 A JP 2015155400A JP 2015005492 A JP2015005492 A JP 2015005492A JP 2015005492 A JP2015005492 A JP 2015005492A JP 2015155400 A JP2015155400 A JP 2015155400A
- Authority
- JP
- Japan
- Prior art keywords
- corneal endothelial
- cells
- medium
- endothelial cells
- human corneal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000399 corneal endothelial cell Anatomy 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 238000002054 transplantation Methods 0.000 title claims description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 89
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 28
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 28
- 239000002609 medium Substances 0.000 claims description 80
- 239000003636 conditioned culture medium Substances 0.000 claims description 36
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 32
- 238000012258 culturing Methods 0.000 claims description 27
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 18
- 230000008694 endothelial dysfunction Effects 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 12
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 206010010996 Corneal degeneration Diseases 0.000 claims description 6
- 201000004781 bullous keratopathy Diseases 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 239000006143 cell culture medium Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010011033 Corneal oedema Diseases 0.000 claims description 4
- 201000002287 Keratoconus Diseases 0.000 claims description 4
- 206010047642 Vitiligo Diseases 0.000 claims description 4
- 210000005252 bulbus oculi Anatomy 0.000 claims description 4
- 201000004778 corneal edema Diseases 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 230000003511 endothelial effect Effects 0.000 abstract description 2
- 230000007257 malfunction Effects 0.000 abstract 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 21
- 239000012894 fetal calf serum Substances 0.000 description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 20
- 239000012124 Opti-MEM Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000003761 preservation solution Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 229960005070 ascorbic acid Drugs 0.000 description 10
- 235000010323 ascorbic acid Nutrition 0.000 description 10
- 239000011668 ascorbic acid Substances 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 102000015336 Nerve Growth Factor Human genes 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229940053128 nerve growth factor Drugs 0.000 description 7
- 239000003590 rho kinase inhibitor Substances 0.000 description 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 7
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 210000000871 endothelium corneal Anatomy 0.000 description 6
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- 101800003838 Epidermal growth factor Proteins 0.000 description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
- 102000014429 Insulin-like growth factor Human genes 0.000 description 5
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940116977 epidermal growth factor Drugs 0.000 description 5
- 239000012581 transferrin Substances 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100037241 Endoglin Human genes 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 102100025304 Integrin beta-1 Human genes 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102100022464 5'-nucleotidase Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000000568 rho-Associated Kinases Human genes 0.000 description 2
- 108010041788 rho-Associated Kinases Proteins 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- GBOKNHVRVRMECW-UHFFFAOYSA-N 1-pyridin-4-yl-3-(2,4,6-trichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC(Cl)=C1NC(=O)NC1=CC=NC=C1 GBOKNHVRVRMECW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ILDBNQGLZFSHQZ-UTLKBRERSA-N 2-amino-1-[(3s)-3-methyl-4-(4-methylisoquinolin-5-yl)sulfonyl-1,4-diazepan-1-yl]ethanone;dihydrochloride Chemical compound Cl.Cl.C[C@H]1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 ILDBNQGLZFSHQZ-UTLKBRERSA-N 0.000 description 1
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical compound C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- IYOZTVGMEWJPKR-YWRZDDHQSA-N C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 Chemical compound C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-YWRZDDHQSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004045 bowman membrane Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- NMCHYWGKBADVMK-UHFFFAOYSA-N fenetylline Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCNC(C)CC1=CC=CC=C1 NMCHYWGKBADVMK-UHFFFAOYSA-N 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- -1 pH adjusters Chemical compound 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
本発明は，ヒトへの移植用に調製されたヒト角膜内皮細胞を含有する組成物に関し，より詳しくは，エピガロカテキンガレートを含有する溶液中にヒト角膜内皮細胞を含んでなる，ヒトへの移植用に調製された組成物に関する。 The present invention relates to a composition containing human corneal endothelial cells prepared for transplantation into humans, and more particularly, to humans comprising human corneal endothelial cells in a solution containing epigallocatechin gallate. The present invention relates to a composition prepared for transplantation.
角膜は，外側から内側に向かって，角膜上皮，ボーマン膜，角膜実質層，デスメ膜，角膜内皮の５層の細胞層から成る透明な組織であり，血管はないが神経は分布している。角膜の透明度は，角膜実質層と角膜内皮によって維持される。 The cornea is a transparent tissue consisting of five cell layers, corneal epithelium, Bowman's membrane, corneal stroma, Descemet's membrane, and corneal endothelium, from outside to inside, and there are no blood vessels but nerves are distributed. The transparency of the cornea is maintained by the corneal stroma and the corneal endothelium.
角膜内皮機能不全は失明の主要な原因の一つであり，角膜の透明度を維持するための角膜内皮の機能が喪失することにより，視野が損なわれる。角膜内皮機能不全は，角膜内皮が変性，壊死又は物理的に脱落する等によって引き起こされる。角膜内皮細胞の機能不全により引き起こされる疾患として，水疱性角膜症がある。水疱性角膜症は，角膜内皮細胞の機能の一つである角膜内の水分量を調節するポンプ機能が損なわれ，その結果角膜内の水分が排出されなくなり，角膜が浮腫状に混濁する重度の角膜内皮機能不全である。また，浮腫のために角膜上皮が剥離する場合もある。角膜内皮の機能不全を原因とする疾患には，水疱性角膜症の他に，角膜浮腫，角膜白斑，円錐角膜等が挙げられる。 Corneal endothelial dysfunction is one of the major causes of blindness, and the loss of corneal endothelium function to maintain corneal transparency results in impaired vision. Corneal endothelial dysfunction is caused by degeneration, necrosis, or physical loss of the corneal endothelium. Bullous keratopathy is a disease caused by dysfunction of corneal endothelial cells. Bullous keratopathy is a severe cerebral edema-like turbidity that impairs the pumping function that regulates the amount of water in the cornea, which is one of the functions of corneal endothelial cells. Corneal endothelial dysfunction. In addition, corneal epithelium may be detached due to edema. Diseases caused by corneal endothelial dysfunction include corneal edema, corneal vitiligo, keratoconus, etc. in addition to bullous keratopathy.
角膜内皮の機能不全を原因とする疾患の治療法として，角膜内皮細胞を培養し，これを角膜内皮機能不全患者に移植して角膜内皮の機能を回復することが検討されている。例えば，角膜内皮細胞を羊膜上で培養して移植用の角膜内皮様シートを製造する方法が報告されている（特許文献１及び２）。また，角膜内皮細胞をフィブロネクチンで被覆したコラーゲンシート上で培養して移植用の角膜内皮様シートを製造する方法（特許文献３），角膜内皮細胞をセルロース基材上で培養して移植用の角膜内皮様シートを製造する方法（特許文献４）も報告されている。また，角膜内皮細胞の培養に用いる培地についても，種々のものが報告されている（非特許文献１）。 As a treatment method for diseases caused by corneal endothelial dysfunction, corneal endothelial cells are cultured and transplanted to patients with corneal endothelial dysfunction to restore the function of the corneal endothelium. For example, a method for producing a corneal endothelium-like sheet for transplantation by culturing corneal endothelial cells on amniotic membrane has been reported (Patent Documents 1 and 2). In addition, a method of producing a corneal endothelium-like sheet for transplantation by culturing corneal endothelial cells on a collagen sheet coated with fibronectin (Patent Document 3), and a corneal endothelium by culturing corneal endothelial cells on a cellulose substrate. A method for producing an endothelium-like sheet (Patent Document 4) has also been reported. Various media have also been reported for use in culturing corneal endothelial cells (Non-patent Document 1).
角膜内皮細胞の培養における問題として，角膜内皮細胞が培養中に形態変化し，線維芽細胞様細胞となることがある（特許文献４及び非特許文献２）。そこで，角膜内皮細胞をRhoキナーゼ阻害剤の存在下で培養することにより，角膜内皮細胞の形態変化を防止するとともに，角膜内皮細胞の接着を促進し，高い細胞密度を持った移植用の角膜内皮細胞層を製造する方法が報告されている（特許文献５）。なお，RhoキナーゼはヒトES細胞が培養時に細胞死するときに活性化することが知られており，Rhoキナーゼを阻害するROCK阻害剤（(＋)-トランス-4-（1-アミノエチル）-1-(4-ピリジルカルバモイル)シクロヘキサン，1-(5-イソキノリンスルホニル)ホモピペラジン等）は，かかる細胞死を阻害することが知られている（非特許文献３）。その他，TGFβ阻害剤（ALK-5阻害剤等）が培養中の角膜内皮細胞の形態変化を防止する効果を有することが報告されている（特許文献６）。 As a problem in culturing corneal endothelial cells, corneal endothelial cells may undergo morphological changes during culturing and become fibroblast-like cells (Patent Document 4 and Non-Patent Document 2). Therefore, culturing corneal endothelial cells in the presence of a Rho kinase inhibitor prevents corneal endothelial cell morphological changes, promotes corneal endothelial cell adhesion, and has a high cell density for transplantation. A method for producing a cell layer has been reported (Patent Document 5). Rho kinase is known to be activated when human ES cells die during culture. ROCK inhibitor ((+)-trans-4- (1-aminoethyl)- 1- (4-pyridylcarbamoyl) cyclohexane, 1- (5-isoquinolinesulfonyl) homopiperazine, etc.) are known to inhibit such cell death (Non-patent Document 3). In addition, it has been reported that TGFβ inhibitors (ALK-5 inhibitors and the like) have an effect of preventing morphological changes of corneal endothelial cells during culture (Patent Document 6).
角膜組織から得られた角膜内皮細胞を，角膜内皮細胞培養用培地を用いて培養し増殖させて得られた細胞は，一旦凍結させると角膜内皮細胞としての機能を喪失するおそれがある。従って，移植用に用いる角膜内皮細胞は，培養して増殖させた後，凍結保存等することなく，細胞懸濁液等の形態の移植用の組成物として調製させた後に，患者に速やかに移植することが好ましい。しかし，例えば，移植用の細胞を細胞懸濁液として調製してから，その細胞懸濁液を患者に移植するまでに，施術の準備等の都合により時間を要することも考えられる。そうすると，その間に折角調製した細胞が，細胞死等の経時的変化を起こし，もはや移植用の細胞として使用できない事態が起こりうる。かかる事態を回避するため，移植用の細胞は，移植用の組成物として調製してからの経時的変化が防止されて，可能な限り長時間，移植用の細胞として適した状態に保たれることが望まれる。角膜内皮細胞の経時的変化を防止するための保存液として，Rhoキナーゼを阻害するROCK阻害剤である１−（５−イソキノリンスルホニル）ホモピペラジン（ファスジル），（＋）−トランス−４−（１−アミノエチル）−１−（４−ピリジルカルバモイル）シクロヘキサン（Ｙ−２７６３２）を含有する保存液が報告されている（特許文献７）。 Cells obtained by culturing and proliferating corneal endothelial cells obtained from corneal tissue using a corneal endothelial cell culture medium may lose their function as corneal endothelial cells once frozen. Therefore, corneal endothelial cells used for transplantation are cultured and proliferated, and after being prepared as a composition for transplantation in the form of a cell suspension or the like without being cryopreserved, they are promptly transplanted to the patient. It is preferable to do. However, for example, it may be time-consuming for the preparation of the treatment and the like after preparing the cells for transplantation as a cell suspension and transplanting the cell suspension to a patient. As a result, the cells prepared during this time may undergo changes over time such as cell death, and may no longer be used as cells for transplantation. To avoid this situation, cells for transplantation are kept in a suitable state as cells for transplantation for as long as possible, preventing changes over time after preparation as a composition for transplantation. It is hoped that. As a preservation solution for preventing changes in corneal endothelial cells over time, 1- (5-isoquinolinesulfonyl) homopiperazine (fasudil), (+)-trans-4- (1), which is a ROCK inhibitor that inhibits Rho kinase, is used. A preservation solution containing -aminoethyl) -1- (4-pyridylcarbamoyl) cyclohexane (Y-27632) has been reported (Patent Document 7).
エピガロカテキンガレートは，カテキンの一種であり抗酸化活性を有する。細胞又は臓器の保存液として，エピガロカテキンガレートを含有するものが種々報告されている（特許文献８〜１５）。また，無機イオン類，Ｄ−グルコース，アミノ酸，pH調整剤，及びエピガロカテキンガレート等を含有し，ヒト角膜内皮組織を4℃で少なくとも2週間好適に保存し得る組織用冷蔵保存液であるセリオキープ／ThelioKeep（登録商標，株式会社バイオベルデ）が市販されている。 Epigallocatechin gallate is a kind of catechin and has antioxidant activity. Various preservation solutions for cells or organs containing epigallocatechin gallate have been reported (Patent Documents 8 to 15). Seriokeep is a refrigerated preservation solution for tissues that contains inorganic ions, D-glucose, amino acids, pH adjusters, epigallocatechin gallate, etc., and can suitably preserve human corneal endothelial tissue at 4 ° C. for at least 2 weeks. / ThelioKeep (registered trademark, Bioverde) is commercially available.
上記背景の下で，本発明の目的は，ヒトへの移植用に調製されたヒト角膜内皮細胞を含有する組成物に関し，詳しくは，エピガロカテキンガレートを含有するヒト角膜内皮細胞を懸濁させた細胞懸濁液からなる，低温で少なくとも72時間保存可能な，ヒトへの移植用の組成物を提供することである。 In view of the above background, an object of the present invention relates to a composition containing human corneal endothelial cells prepared for transplantation into humans, and more specifically, suspending human corneal endothelial cells containing epigallocatechin gallate. It is intended to provide a composition for transplantation into humans that can be stored at low temperature for at least 72 hours.
上記目的に向けた研究において，本発明者らは，鋭意検討を重ねた結果，ヒト角膜内皮細胞が，エピガロカテキンガレートを含有する溶液中で比較的長時間，懸濁状態で保存できることを見出し，本発明を完成した。すなわち，本発明は以下を提供する。
（１）エピガロカテキンガレートを含有する溶液中にヒト角膜内皮細胞を含んでなる，角膜内皮機能不全患者にヒト角膜内皮細胞を移植するために調製された，組成物。
（２）該エピガロカテキンガレートの濃度が15〜35μg／mLである，上記（１）の組成物。
（３）該エピガロカテキンガレートの濃度が25μg／mLである，上記（１）の組成物。
（４）該ヒト角膜内皮細胞の濃度が，1×106〜4×106個／mLである，上記（１）〜（３）の何れかの組成物。
（５）該ヒト角膜内皮細胞の濃度が， 2.5x106個／mLである，上記（１）〜（３）の何れかの組成物。
（６）該角膜内皮機能不全患者が，水疱性角膜症，角膜浮腫，角膜白斑及び円錐角膜からなる群から選択される何れかの疾患に罹患しているものである，上記（１）〜（５）の何れかの組成物。
（７）一つの眼球あたり，１回に1×105〜8×105個の該ヒト角膜内皮細胞が投与されるものである，上記（１）〜（６）の何れかの組成物。
（８）該調製後に，凍結されることなく該移植に用いられるものである，上記（１）〜（７）の何れかの組成物。
（９）該ヒト角膜内皮細胞が，ヒト角膜組織から得たヒト角膜内皮細胞を，間葉系幹細胞の馴化培地からなる又は該馴化培地を含有する，角膜内皮細胞培養用培地を用いて培養して増殖させたものである，上記（１）〜（８）の何れかの組成物。
（１０）該角膜内皮細胞培養用培地が，該馴化培地を0.5〜50％(v/v)の比率で含有するものである，上記（９）の組成物。
（１１）該角膜内皮細胞培養用培地が，該馴化培地を3〜10％(v/v)の比率で含有するものである，上記（９）の組成物。
（１２）該馴化培地が，該間葉系幹細胞を，コンドロイチン硫酸又はその塩を0.04〜0.12％(w/v)濃度で含有する培地で培養することにより得られたものである，上記（９）〜（１１）の何れかの組成物。
（１３）該コンドロイチン硫酸又はその塩の濃度が0.08％(w/v)である，上記（１２）の組成物。
As a result of intensive studies, the present inventors have found that human corneal endothelial cells can be stored in a suspension state for a relatively long time in a solution containing epigallocatechin gallate. The present invention has been completed. That is, the present invention provides the following.
(1) A composition prepared for transplanting human corneal endothelial cells to a corneal endothelial dysfunction patient, comprising human corneal endothelial cells in a solution containing epigallocatechin gallate.
(2) The composition according to (1) above, wherein the concentration of epigallocatechin gallate is 15 to 35 μg / mL.
(3) The composition according to (1) above, wherein the concentration of epigallocatechin gallate is 25 μg / mL.
(4) The composition according to any one of (1) to (3) above, wherein the concentration of the human corneal endothelial cells is 1 × 10 6 to 4 × 10 6 cells / mL.
(5) The composition according to any one of (1) to (3) above, wherein the concentration of the human corneal endothelial cells is 2.5 × 10 6 cells / mL.
(6) The above (1) to (1), wherein the corneal endothelial dysfunction patient suffers from any disease selected from the group consisting of bullous keratopathy, corneal edema, corneal vitiligo and keratoconus. The composition according to any one of 5).
(7) The composition according to any one of (1) to (6) above, wherein 1 × 10 5 to 8 × 10 5 human corneal endothelial cells are administered per eye.
(8) The composition according to any one of (1) to (7), which is used for the transplantation without being frozen after the preparation.
(9) The human corneal endothelial cell is cultured from a corneal endothelial cell culture medium comprising a conditioned medium of a mesenchymal stem cell or containing the conditioned medium. The composition according to any one of the above (1) to (8), which is proliferated in this manner.
(10) The composition according to (9) above, wherein the corneal endothelial cell culture medium contains the conditioned medium at a ratio of 0.5 to 50% (v / v).
(11) The composition according to (9) above, wherein the medium for corneal endothelial cell culture contains the conditioned medium at a ratio of 3 to 10% (v / v).
(12) The conditioned medium obtained by culturing the mesenchymal stem cells in a medium containing chondroitin sulfate or a salt thereof at a concentration of 0.04 to 0.12% (w / v) (9) ) To (11).
(13) The composition according to (12), wherein the concentration of the chondroitin sulfate or a salt thereof is 0.08% (w / v).
本発明によれば，高い細胞生存率を維持し,角膜内皮機能不全患者に移植し得るヒト角膜内皮細胞を含む組成物を得ることができるので，角膜内皮機能不全患者に移植するために，ヒト角膜内皮細胞を調製する際の時間的制約が大幅に緩和される。例えば，ヒト角膜内皮細胞を含む組成物が調製後72時間保存可能であれば，施術の準備等の都合により手術日が当初の予定より1〜3日遅れる場合にも対応できる。また，輸送に1〜3日を要する遠方の医療施設にも供給可能となるので，例えば，製造拠点を日本国内に1箇所設けるだけで，日本全国への供給体制を整えることができる。 According to the present invention, a composition containing human corneal endothelial cells that can maintain a high cell viability and can be transplanted to a patient with corneal endothelial dysfunction can be obtained. Time constraints in preparing corneal endothelial cells are greatly relaxed. For example, if a composition containing human corneal endothelial cells can be stored for 72 hours after preparation, it is possible to cope with the case where the operation date is delayed by 1 to 3 days from the original schedule due to the preparation of the operation. In addition, because it can be supplied to distant medical facilities that require 1 to 3 days for transportation, for example, it is possible to set up a supply system throughout Japan simply by providing one manufacturing base in Japan.
本発明において，ヒト角膜内皮細胞は，ヒト角膜組織から分離されたものである。かかるヒト角膜組織は，研究用ヒト角膜組織として市販されているものを用いることができるが，ヘルシンキ宣言，各国法令，各国規制当局の通知等によって定められた基準，及びこれらに基づき作成された倫理規定を遵守することを条件に，その他のヒト角膜組織を使用することもできる。 In the present invention, human corneal endothelial cells are those isolated from human corneal tissue. As such human corneal tissue, commercially available human corneal tissue for research can be used, but the standards established by the Declaration of Helsinki, national laws and regulations, notifications from national regulatory authorities, etc., and the ethics prepared based on these standards. Other human corneal tissue can also be used, provided that the regulations are observed.
本発明におけるヒト角膜内皮細胞は，ヒト角膜組織から角膜内皮細胞を得て，これを細胞培養用フラスコ中で，間葉系幹細胞（MSC）の馴化培地を含む角膜内皮細胞培養用培地を用いて培養して増殖させて得られたものであり，特に，顕微鏡下で観察したときに，細胞培養用フラスコの底面上で一層の多角形の形状を示す細胞，及びこれらをトリプシン等の酵素で処理した後に溶液中に懸濁させた細胞のことをいう。 The human corneal endothelial cells in the present invention are obtained by obtaining corneal endothelial cells from human corneal tissue, and using the corneal endothelial cell culture medium containing a conditioned medium of mesenchymal stem cells (MSC) in a cell culture flask. Cells obtained by culturing and growing, especially cells that show a single polygonal shape on the bottom of a cell culture flask when viewed under a microscope, and these are treated with an enzyme such as trypsin After that, it refers to the cells suspended in the solution.
間葉系幹細胞（MSC）の馴化培地を調製するために用いられる間葉系幹細胞は，未分化の状態で増殖し，少なくとも2種類の細胞へ分化することが可能な，間葉に由来する幹細胞又はその前駆細胞である。間葉系幹細胞から分化誘導される細胞は，例えば骨芽細胞，軟骨芽細胞，脂肪芽細胞である。 Mesenchymal stem cells used to prepare a conditioned medium of mesenchymal stem cells (MSC) are stem cells derived from mesenchyme that can proliferate in an undifferentiated state and differentiate into at least two types of cells Or its precursor cells. Cells that are induced to differentiate from mesenchymal stem cells are, for example, osteoblasts, chondroblasts, and lipoblasts.
本発明において用いられる間葉系幹細胞は，好ましくはヒト間葉系幹細胞（hMSC）である。MSCは，骨髄，脂肪組織，歯髄，臍帯血，胎盤，羊膜等，種々の組織から取得できることが知られている。本発明において使用するMSCは，これら取得先の組織に関わらず，いずれのものでも使用できるが，好ましくは，骨髄由来のMSCである。また，MSCは，種々の方法により取得できるが，例えば骨髄由来のMSCの場合，特許文献（特表平7-500001）等に記載の手法で取得することができる。 The mesenchymal stem cell used in the present invention is preferably a human mesenchymal stem cell (hMSC). It is known that MSC can be obtained from various tissues such as bone marrow, adipose tissue, dental pulp, umbilical cord blood, placenta, and amniotic membrane. As the MSC used in the present invention, any MSC can be used regardless of the tissue from which the material is obtained. However, bone marrow-derived MSC is preferable. MSC can be obtained by various methods. For example, in the case of MSC derived from bone marrow, it can be obtained by the method described in the patent document (Japanese Patent Publication No. 7-500001).
本発明において用いられるヒト間葉系幹細胞は，表面抗原の発現パターンによりさらに特定することができ，特異的抗体を用いたフローサイトメトリー解析をした場合，好ましくは，CD29，CD44及びCD105が陽性であり，CD34及びCD45が陰性であり，より好ましくは，CD29，CD44，CD73，CD90及びCD105が陽性であり，CD34及びCD45が陰性であり，さらに好ましくはCD13，CD29，CD44，CD73，CD90，CD105及びCD166が陽性であり，CD34及びCD45が陰性であり，最も好ましくは，CD13，CD29，CD44，CD49a，CD49e，CD73，CD90，CD105及びCD166が陽性であり，CD34及びCD45が陰性である。 The human mesenchymal stem cells used in the present invention can be further specified by the expression pattern of the surface antigen. When flow cytometry analysis using a specific antibody is performed, CD29, CD44 and CD105 are preferably positive. Yes, CD34 and CD45 are negative, more preferably CD29, CD44, CD73, CD90 and CD105 are positive, CD34 and CD45 are negative, more preferably CD13, CD29, CD44, CD73, CD90, CD105 And CD166 are positive, CD34 and CD45 are negative, most preferably CD13, CD29, CD44, CD49a, CD49e, CD73, CD90, CD105, and CD166 are positive, and CD34 and CD45 are negative.
本発明において，間葉系幹細胞の馴化培地（MSC馴化培地）というときは，培地中で間葉系幹細胞を培養した後に，該細胞を除去して得られる培地のことをいう。 In the present invention, a conditioned medium of mesenchymal stem cells (MSC conditioned medium) refers to a medium obtained by culturing mesenchymal stem cells in a medium and then removing the cells.
本発明において，MSC馴化培地を調製するためにMSCの培養に使用するMSC培養用培地は，MSCを培養できる培地である限り特に制限はなく，例えば，ウシ胎児血清（FCS）を含有するフィットン−ジャクソン改変BGJb培地，ウシ胎児血清（FCS）を添加したＦ−１２栄養素混合物培地（Ham），ウシ胎児血清（FCS）を添加したDMEM培地，ウシ胎児血清(FCS) を添加したダルベッコ／ハムF12 1:1混合培地，ウシ胎児血清(FCS)及び4mMアラニルグルタミンを添加したダルベッコ／ハムF12 1:1混合培地，ウシ胎児血清（FCS）を添加したOpti-MEMTM I Reduced-Serum Medium, Liquid（Gibco社製），ウシ胎児血清（FCS），200μg/mL CaCl2・2H2O及び0.08％(w/v) コンドロイチン硫酸又はその塩，例えばナトリウム塩を添加したOpti-MEMTM I Reduced-Serum Medium, Liquid（Gibco社製）等が使用できる。上記培地に含まれるFCSの濃度は，好ましくは5〜20％(v/v)であり，より好ましくは6〜12％(v/v)であり，さらに好ましくは7.5〜10.5％(v/v)であり，特にOpti-MEMTM I Reduced-Serum Medium, Liquid（Gibco社製）を用いた場合は約8％(v/v)，その他の基礎培地を用いた場合は約10％(v/v)である。なお，Opti-MEMTM I Reduced-Serum Medium, Liquid（Gibco社製）は，イーグル基礎培地に，HEPES，重炭酸ナトリウム，ヒポキサンチン，チミジン，ピルビン酸ナトリウム，L-グルタミン，インスリン，トランスフェリン等を添加した培地である。 In the present invention, the MSC culture medium used for culturing MSC to prepare the MSC-conditioned medium is not particularly limited as long as it is a medium capable of culturing MSC. For example, Fitton containing fetal calf serum (FCS) is used. -Jackson modified BGJb medium, F-12 nutrient mixture medium (Ham) supplemented with fetal calf serum (FCS), DMEM medium supplemented with fetal calf serum (FCS), Dulbecco / ham F12 supplemented with fetal calf serum (FCS) Dulbecco / Ham F12 1: 1 mixed medium supplemented with 1: 1 mixed medium, fetal calf serum (FCS) and 4 mM alanylglutamine, Opti-MEM ™ I Reduced-Serum Medium, Liquid supplemented with fetal calf serum (FCS) (Gibco), fetal calf serum (FCS), 200 μg / mL CaCl 2 · 2H 2 O and 0.08% (w / v) chondroitin sulfate or its salt, eg sodium salt Opti-MEM TM I Reduced-Serum Medium, Liquid (manufactured by Gibco), etc. can be used. The concentration of FCS contained in the medium is preferably 5 to 20% (v / v), more preferably 6 to 12% (v / v), and even more preferably 7.5 to 10.5% (v / v). In particular, when using Opti-MEM ™ I Reduced-Serum Medium, Liquid (Gibco), approximately 8% (v / v), and when using other basal media, approximately 10% (v / v) v). In addition, Opti-MEM TM I Reduced-Serum Medium, Liquid (manufactured by Gibco) added HEPES, sodium bicarbonate, hypoxanthine, thymidine, sodium pyruvate, L-glutamine, insulin, transferrin, etc. to Eagle's basic medium Medium.
本発明において，MSC馴化培地を調製するためのMSCの培養は，MSCを，細胞培養用フラスコに，好ましくは1×103〜2×104個／cm2の密度で，より好ましくは2×103〜1×104個／cm2の密度で，さらに好ましくは3〜5×103個／cm2の密度で播種して開始される。また，このとき培養面積1cm2当たりに加えられるMSC培養用培地の量は，好ましくは0.15〜0.5mLであり，さらに好ましくは0.2〜0.3mLである。また，このとき用いられる細胞培養用フラスコは，好ましくは底面がコラーゲン，ファイブロネクチン等でコートされたフラスコ，又は底面がマイナスにチャージした官能基で修飾されたフラスコ，例えばプライマリカルチャーウェア（BD社製）である。培養開始後，MSCは，細胞培養用フラスコの底面を，好ましくは30〜80％，さらに好ましくは50〜70％を細胞が占めるまで培養される。次いで培地を回収（初回の回収）し，新しい培地に交換してさらに細胞を培養する。このとき培養面積1cm2当たりに加えられる培地の量は，好ましくは0.15〜0.5mLであり，さらに好ましくは0.2〜0.3mLである。細胞を培地交換後，好ましくは8〜24時間，さらに好ましくは12〜18時間培養した後，培地を回収（第2回の回収）する。さらに，同様にして培地の交換と回収を，好ましくは3〜7回，さらに好ましくは3〜5回繰り返す（第3回以降の回収）。 In the present invention, the MSC culture for preparing the MSC-conditioned medium is carried out in a flask for cell culture, preferably at a density of 1 × 10 3 to 2 × 10 4 cells / cm 2 , more preferably 2 ×. The seeding is started at a density of 10 3 to 1 × 10 4 pieces / cm 2 , more preferably 3 to 5 × 10 3 pieces / cm 2 . At this time, the amount of the MSC culture medium added per 1 cm 2 of the culture area is preferably 0.15 to 0.5 mL, more preferably 0.2 to 0.3 mL. The cell culture flask used at this time is preferably a flask whose bottom surface is coated with collagen, fibronectin or the like, or a flask whose bottom surface is modified with a negatively charged functional group, such as primary cultureware (manufactured by BD). ). After the start of culture, the MSC is cultured until the cells occupy the bottom of the cell culture flask, preferably 30 to 80%, more preferably 50 to 70%. The medium is then recovered (initial recovery), replaced with fresh medium, and further cells are cultured. At this time, the amount of the medium added per 1 cm 2 of the culture area is preferably 0.15 to 0.5 mL, and more preferably 0.2 to 0.3 mL. The cells are cultured after the medium exchange, preferably for 8 to 24 hours, more preferably for 12 to 18 hours, and then the medium is recovered (second recovery). Further, the medium exchange and recovery are preferably repeated 3 to 7 times, more preferably 3 to 5 times (collection after the third time).
初回の回収，第2回の回収及び第3回以降の回収で回収された培地は，いずれもMSC馴化培地として使用可能であり，これらを混ぜ合わせてMSC馴化培地とすることもできるが，第2回の回収以降で回収された培地がMSC馴化培地として特に好適に用いられる。また，このときのMSC馴化培地の回収は，好ましくは培養液を遠心して上清を回収することにより行う。回収後のMSC馴化培地は，適宜膜ろ過等により除菌，濃縮をすることもできる。また，MSC馴化培地は冷凍することができるので，凍結状態で長期保存，輸送等が可能である。但し，MSC馴化培地は4℃でも10〜14日間は保存可能である。 The medium collected in the first collection, the second collection, and the third and subsequent collections can be used as the MSC-conditioned medium, and these can be mixed to form the MSC-conditioned medium. The medium collected after the second collection is particularly preferably used as the MSC-conditioned medium. The MSC-conditioned medium at this time is preferably collected by centrifuging the culture medium and collecting the supernatant. The recovered MSC-conditioned medium can be sterilized and concentrated as appropriate by membrane filtration or the like. In addition, since MSC-conditioned media can be frozen, it can be stored and transported in the frozen state for a long time. However, MSC-conditioned media can be stored at 4 ° C for 10-14 days.
本発明において，MSC馴化培地は，ヒト角膜内皮細胞培養用の培地としてそのまま使用可能であるが，上皮増殖因子（EGF），塩基性線維芽細胞増殖因子（bFGF），神経成長因子（NGF），インスリン，トランスフェリン，及びインスリン様成長因子（IGF）等の成長因子，並びにアスコルビン酸，コンドロイチン硫酸，及び抗生物質等から選択されるその他の成分を，一種若しくはニ種以上，適宜添加して使用することもできる。培地にEGFを添加する場合，その濃度は，好ましくは1〜50ng/mLであり，より好ましくは5〜40ng/mLであり，さらに好ましくは約20ng/mLである。培地にbFGFを添加する場合，その濃度は，好ましくは1〜20ng/mLであり，より好ましくは3〜7ng/mLであり，さらに好ましくは約5ng/mLである。培地にNGFを添加する場合，その濃度は，好ましくは1〜25ng/mLであり，より好ましくは3〜7ng/mLであり，さらに好ましくは約5ng/mLである。インスリンを添加する場合，その濃度は，好ましくは1〜200μg/mLである。トランスフェリンを添加する場合，その濃度は，好ましくは1〜200μg/mLである。培地にアスコルビン酸（又はその塩）を添加する場合，その濃度は，アスコルビン酸として，好ましくは5〜40μg/mLであり，より好ましくは10〜30μg/mLであり，さらに好ましくは約20μg/mLである。コンドロイチン硫酸（又はその塩）を添加する場合，その濃度は，好ましくは0.04〜0.12％(w/v)であり，より好ましくは0.06〜0.10％(w/v)であり，さらに好ましくは約0.08％(w/v)である。 In the present invention, the MSC-conditioned medium can be used as it is as a medium for culturing human corneal endothelial cells, but epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), nerve growth factor (NGF), Use one or more kinds of other ingredients selected from growth factors such as insulin, transferrin, and insulin-like growth factor (IGF), ascorbic acid, chondroitin sulfate, and antibiotics as appropriate. You can also. When EGF is added to the medium, the concentration is preferably 1 to 50 ng / mL, more preferably 5 to 40 ng / mL, and even more preferably about 20 ng / mL. When bFGF is added to the medium, the concentration is preferably 1 to 20 ng / mL, more preferably 3 to 7 ng / mL, and even more preferably about 5 ng / mL. When NGF is added to the medium, the concentration is preferably 1 to 25 ng / mL, more preferably 3 to 7 ng / mL, and even more preferably about 5 ng / mL. When insulin is added, the concentration is preferably 1 to 200 μg / mL. When transferrin is added, the concentration is preferably 1 to 200 μg / mL. When ascorbic acid (or a salt thereof) is added to the medium, the concentration of ascorbic acid is preferably 5 to 40 μg / mL, more preferably 10 to 30 μg / mL, and even more preferably about 20 μg / mL. It is. When chondroitin sulfate (or a salt thereof) is added, the concentration is preferably 0.04 to 0.12% (w / v), more preferably 0.06 to 0.10% (w / v), and even more preferably about 0.08. % (W / v).
MSC馴化培地は，そのままヒト角膜内皮細胞培養用の培地として使用することができるが，MSC馴化培地を他の培地に添加したものをヒト角膜内皮細胞培養用の培地として使用することもできる。この場合の，他の培地に添加するMSC馴化培地の量は，他の培地の液量に対して，好ましくは0.5〜80％(v/v)であり，より好ましくは0.5〜50％(v/v)であり，さらに好ましくは3〜10％(v/v)の液量である。 The MSC-conditioned medium can be used as it is as a medium for culturing human corneal endothelial cells, but a medium obtained by adding MSC-conditioned medium to other media can also be used as a medium for culturing human corneal endothelial cells. In this case, the amount of the MSC-conditioned medium added to the other medium is preferably 0.5 to 80% (v / v), more preferably 0.5 to 50% (v / v), more preferably 3 to 10% (v / v).
MSC馴化培地を添加する上記の他の培地は，先行文献（Peh GSL. et al., Transplantation 91, 811-9 (2011)等）に開示されているヒト角膜内皮細胞培養用の培地が好ましく，例えば，8％(v/v) FCS，200μg/mL CaCl2・2H2O，0.08％(w/v) コンドロイチン硫酸，20μg/mL アスコルビン酸, 5ng/mL EGFを添加したOpti-MEM I Reduced-Serum Medium, Liquid培地（Gibco社製）である。また，培地に，上皮増殖因子（EGF），塩基性線維芽細胞増殖因子（bFGF），神経成長因子（NGF），インスリン，トランスフェリン，インスリン様成長因子（IGF）等の成長因子，アスコルビン酸，コンドロイチン硫酸，抗生物質等から選択されるその他の成分を，一種又はニ種以上，適宜添加して使用することもできる。培地にEGFを添加する場合，その濃度は，好ましくは1〜50ng/mLであり，より好ましくは5〜40ng/mLであり，さらに好ましくは約20ng/mLである。培地にbFGFを添加する場合，その濃度は，好ましくは1〜20ng/mLであり，より好ましくは3〜7ng/mLであり，さらに好ましくは約5ng/mLである。培地にNGFを添加する場合，その濃度は，好ましくは1〜25ng/mLであり，より好ましくは3〜7ng/mLであり，さらに好ましくは約5ng/mLである。インスリンを添加する場合，その濃度は，好ましくは1〜200μg/mLである。トランスフェリンを添加する場合，その濃度は，1〜200μg/mLである。培地にアスコルビン酸（又はその塩）を添加する場合，その濃度は，アスコルビン酸として，好ましくは5〜40μg/mLであり，より好ましくは10〜30μg/mLであり，さらに好ましくは約20μg/mLである。コンドロイチン硫酸（又はその塩）を添加する場合，その濃度は，好ましくは0.04〜0.12％(w/v)であり，より好ましくは0.06〜0.10％(w/v)であり，さらに好ましくは約0.08％(w/v)である。また，培地には，適宜，ゲンタマイシン等の抗生物質，フェノールレッド等のpH指示薬を添加することもできる。 The above-mentioned other medium to which MSC conditioned medium is added is preferably a medium for culturing human corneal endothelial cells disclosed in a prior document (Peh GSL. Et al., Transplantation 91, 811-9 (2011), etc.) For example, Opti-MEM I Reduced- supplemented with 8% (v / v) FCS, 200μg / mL CaCl 2 · 2H 2 O, 0.08% (w / v) chondroitin sulfate, 20μg / mL ascorbic acid, 5ng / mL EGF Serum Medium, Liquid medium (Gibco). In addition, growth medium such as epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), nerve growth factor (NGF), insulin, transferrin, insulin-like growth factor (IGF), ascorbic acid, chondroitin One or more other components selected from sulfuric acid, antibiotics and the like can be added as appropriate and used. When EGF is added to the medium, the concentration is preferably 1 to 50 ng / mL, more preferably 5 to 40 ng / mL, and even more preferably about 20 ng / mL. When bFGF is added to the medium, the concentration is preferably 1 to 20 ng / mL, more preferably 3 to 7 ng / mL, and even more preferably about 5 ng / mL. When NGF is added to the medium, the concentration is preferably 1 to 25 ng / mL, more preferably 3 to 7 ng / mL, and even more preferably about 5 ng / mL. When insulin is added, the concentration is preferably 1 to 200 μg / mL. When transferrin is added, the concentration is 1–200 μg / mL. When ascorbic acid (or a salt thereof) is added to the medium, the concentration of ascorbic acid is preferably 5 to 40 μg / mL, more preferably 10 to 30 μg / mL, and even more preferably about 20 μg / mL. It is. When chondroitin sulfate (or a salt thereof) is added, the concentration is preferably 0.04 to 0.12% (w / v), more preferably 0.06 to 0.10% (w / v), and even more preferably about 0.08. % (W / v). In addition, an antibiotic such as gentamicin and a pH indicator such as phenol red can be appropriately added to the medium.
本発明において，ヒト角膜内皮細胞培養用の培地として，ヘキサヒドロ-1-(イソキノリン-5-イルスルホニル)-1H-1,4-ジアゼピン（ファスジル），1-(5-イソキノリンスルホニル)ホモピペラジン（Y-27632），グリシルH-1152ジヒドロクロリド，3-(4-ピリジル)インドール，N-(4-ピリジル)-N'-(2,4,6-トリクロロフェニル)ウレア等のRhoキナーゼ阻害剤（これらの塩及び水和物を含む）を添加したものを使用することもできる。Rhoキナーゼ阻害剤としてY-27632を添加する場合，その濃度は，好ましくは0.5〜20μMであり，より好ましくは5.0〜15μMであり，さらに好ましくは約10μMである。 In the present invention, as a medium for culturing human corneal endothelial cells, hexahydro-1- (isoquinolin-5-ylsulfonyl) -1H-1,4-diazepine (fasudil), 1- (5-isoquinolinesulfonyl) homopiperazine (Y -27632), glycyl H-1152 dihydrochloride, 3- (4-pyridyl) indole, N- (4-pyridyl) -N '-(2,4,6-trichlorophenyl) urea and other Rho kinase inhibitors (these (Including salts and hydrates) can also be used. When Y-27632 is added as a Rho kinase inhibitor, the concentration is preferably 0.5 to 20 μM, more preferably 5.0 to 15 μM, and even more preferably about 10 μM.
また，ヒト角膜内皮細胞培養用の培地として，SB431542，A-83-01等のALK-5阻害剤（これらの塩及び水和物を含む）を添加したものを使用することもできる。ALK-5阻害剤としてSB431542を添加する場合，その濃度は，好ましくは0.5〜1.5μMであり，より好ましくは0.7〜1.2μMであり，さらに好ましくは約1μMである。ALK-5阻害剤は単独で，又はRhoキナーゼ阻害剤と組み合わせて使用することもできる。 In addition, as a medium for culturing human corneal endothelial cells, a medium supplemented with an ALK-5 inhibitor (including salts and hydrates thereof) such as SB431542 and A-83-01 can also be used. When SB431542 is added as an ALK-5 inhibitor, the concentration is preferably 0.5 to 1.5 μM, more preferably 0.7 to 1.2 μM, and even more preferably about 1 μM. ALK-5 inhibitors can be used alone or in combination with a Rho kinase inhibitor.
本発明において，ヒト角膜内皮細胞の培養は，MSC馴化培地，MSC馴化培地を含有する培地，又はこれらの培地にEGF，bFGF，NGF，IGF，及びインスリン等の成長因子，並びにアスコルビン酸，コンドロイチン硫酸，抗生物質，Rhoキナーゼ阻害剤，及びALK-5阻害剤等から選択されるその他の成分を一種又はニ種以上加えた培地を，ヒト角膜内皮細胞培養用の培地として用いることにより，行われる。また，ヒト角膜内皮細胞の培養において用いられる細胞培養用フラスコは，好ましくは底面がコラーゲン，ファイブロネクチン等でコートされたフラスコ，又は底面がマイナスにチャージされた官能基で修飾されたフラスコ，例えばプライマリカルチャーウェア（BD社製）である。 In the present invention, human corneal endothelial cells are cultured in an MSC-conditioned medium, a medium containing an MSC-conditioned medium, or a growth factor such as EGF, bFGF, NGF, IGF, or insulin, ascorbic acid, chondroitin sulfate. , An antibiotic, a Rho kinase inhibitor, an ALK-5 inhibitor, and the like are used as a medium for culturing human corneal endothelial cells. The cell culture flask used for culturing human corneal endothelial cells is preferably a flask whose bottom surface is coated with collagen, fibronectin or the like, or a flask whose bottom surface is modified with a negatively charged functional group, such as a primary flask. Cultureware (made by BD).
本発明において，ヒト角膜組織から分離されたヒト角膜内皮細胞は，細胞培養用フラスコの底面を，好ましくは20〜50％，より好ましくは25〜40％，さらに好ましくは，約3分の1を細胞が占めるように播種されて初代培養される。初代培養において，ヒト角膜内皮細胞は，好ましくは細胞培養用フラスコの底面の70％以上を占めるまで，より好ましくはコンフルエントになるまで培養される。 In the present invention, human corneal endothelial cells separated from human corneal tissue are preferably 20 to 50%, more preferably 25 to 40%, and still more preferably about one third of the bottom of the cell culture flask. The cells are seeded so that they occupy the primary culture. In the primary culture, the human corneal endothelial cells are cultured until preferably occupying 70% or more of the bottom surface of the cell culture flask, more preferably confluent.
ヒト角膜内皮細胞は，初代培養に引き続いて継代培養することも可能である。継代培養において，ヒト角膜内皮細胞は，細胞培養用フラスコの底面を，好ましくは20〜50％，より好ましくは25〜40％，さらに好ましくは，約3分の1を細胞が占めるように播種される。継代培養において用いるヒト角膜内皮細胞培養用の培地は，初代培養と同じものでも，初代培地と異なる組成の培地でもよい。継代培養において，ヒト角膜内皮細胞は，好ましくは細胞培養用フラスコの底面の70％以上を占めるまで，より好ましくはコンフルエントになるまで培養される。継代培養は，細胞を顕微鏡で観察したときに，細胞の形態等に変化が現れない限り，特に制限なく繰り返し行うことができるが，その回数は，好ましくは1〜5回である。初代培養及びそれに引き続いて行われる継代培養により，ヒト角膜組織から分離されたヒト角膜内皮細胞を200倍以上に増やすことが可能である。 Human corneal endothelial cells can be subcultured following primary culture. In subculture, human corneal endothelial cells are seeded so that the cell occupies the bottom of the cell culture flask, preferably 20-50%, more preferably 25-40%, more preferably about one third. Is done. The medium for culturing human corneal endothelial cells used in the subculture may be the same as the primary culture or a medium having a composition different from that of the primary culture. In the subculture, the human corneal endothelial cells are cultured until preferably occupying 70% or more of the bottom surface of the cell culture flask, more preferably confluent. The subculture can be repeated without particular limitation as long as the cell morphology is not changed when the cells are observed with a microscope, but the number of times is preferably 1 to 5 times. Human corneal endothelial cells isolated from human corneal tissue can be increased 200-fold or more by primary culture and subsequent subculture.
本発明の組成物は，初代培養又は継代培養で得られたヒト角膜内皮細胞を，細胞培養用フラスコからトリプシン，コラゲナーゼ等の酵素を用いて剥離した後，PBS等を用いて洗浄して酵素を除去し，次いで，エピガロカテキンガレートを含有する溶液に懸濁させて調製されるか，エピガロカテキンガレートを含有しない溶液中にヒト角膜内皮細胞を懸濁させた後，この細胞懸濁液にエピガロカテキンガレートを添加して調製される。エピガロカテキンガレートは，下記の式（１）の化学式で示される。 The composition of the present invention comprises a human corneal endothelial cell obtained by primary culture or subculture, detached from a cell culture flask using an enzyme such as trypsin or collagenase, and then washed with PBS or the like to remove the enzyme. And then suspended in a solution containing epigallocatechin gallate or after suspending human corneal endothelial cells in a solution not containing epigallocatechin gallate, this cell suspension It is prepared by adding epigallocatechin gallate. Epigallocatechin gallate is represented by the following chemical formula (1).
本発明の組成物に含まれるエピガロカテキンガレートの濃度は，好ましくは5〜40μg/mL，さらに好ましくは15〜35μg/mL，よりさらに好ましくは約25μg/mLである。また，該組成物に含まれるヒト角膜内皮細胞の密度は，好ましくは1.0×106〜4.0×106個／mL，さらに好ましくは1.5×106〜3.5×106個／mL，最も好ましくは約2.5×106個／mLである。該組成物中において，全てのヒト角膜内皮細胞が単一の細胞に分離した状態であることが好ましいが，一部の細胞が数個又はそれ以上の細胞を含む細胞塊を形成していることは，移植用の細胞として許容される。 The concentration of epigallocatechin gallate contained in the composition of the present invention is preferably 5 to 40 μg / mL, more preferably 15 to 35 μg / mL, and even more preferably about 25 μg / mL. The density of human corneal endothelial cells contained in the composition is preferably 1.0 × 10 6 to 4.0 × 10 6 cells / mL, more preferably 1.5 × 10 6 to 3.5 × 10 6 cells / mL, most preferably About 2.5 × 10 6 cells / mL. In the composition, it is preferable that all human corneal endothelial cells are separated into a single cell, but some of the cells form a cell mass containing several or more cells. Is acceptable as a cell for transplantation.
本発明の組成物は，樹脂製又はガラス製の容器に収納されて，患者に移植されるまで保存される。細胞を収納した状態でこの容器をしばらく静置した場合，容器中でヒト角膜内皮細胞が沈殿する場合もあるが，かかる沈殿状態も，容器を軽く振とう又はピペッティングすることにより懸濁状態になることから，細胞が懸濁された状態にあるとみなすことができる。 The composition of the present invention is stored in a resin or glass container and stored until transplanted to a patient. When this container is left standing for a while with the cells contained, human corneal endothelial cells may precipitate in the container, but such a sedimented state may also be suspended by gently shaking or pipetting the container. Therefore, it can be considered that the cells are in a suspended state.
本発明の組成物は，好ましくは，所望の濃度のエピガロカテキンガレートを添加した無血清培地又は細胞保存液等に，所望の細胞濃度となるように，遠心分離，膜分離等の方法で分離したヒト角膜内皮細胞を懸濁させて調製される。このとき用いられる無血清培地としては，Opti-MEM I Reduced Serum Medium（登録商標，Life Technologies社），イーグルスMEM等が好適であり，細胞保存液としてはセリオキープ／Theliokeep（登録商標，株式会社バイオベルデ）等の市販のものが好適であるが，セリオキープ／Theliokeepが特に好適である。また，リン酸塩，クエン酸塩，血清アルブミン，ゼラチン，アミノ酸（グリシン，グルタミン，アスパラギン，アルギニン，リジン等），グルコース等の単糖類，二糖類，EDTA等のキレート剤，マンニトール等の糖アルコール，塩化ナトリウム，金属イオン，アスコルビン酸等の抗酸化剤，非イオン性界面活性剤，ジメチルスルホキシド，酢酸リンゲル液，pH調整剤等を適宜混合したものを添加して，エピガロカテキンガレートが添加されるべき無血清培地又は細胞保存液を調製することもできる。 The composition of the present invention is preferably separated by a method such as centrifugation or membrane separation into a serum-free medium or a cell preservation solution to which a desired concentration of epigallocatechin gallate is added so as to obtain a desired cell concentration. Prepared by suspending human corneal endothelial cells. As the serum-free medium used at this time, Opti-MEM I Reduced Serum Medium (registered trademark, Life Technologies), Eagles MEM, or the like is suitable. As a cell preservation solution, Seriokeep (registered trademark, Bioverde, Inc.) is used. ) And the like are preferred, but Seriokeep is particularly preferred. In addition, phosphate, citrate, serum albumin, gelatin, amino acids (glycine, glutamine, asparagine, arginine, lysine, etc.), monosaccharides such as glucose, disaccharides, chelating agents such as EDTA, sugar alcohols such as mannitol, Epigallocatechin gallate should be added by adding an appropriate mixture of antioxidants such as sodium chloride, metal ions, ascorbic acid, nonionic surfactant, dimethyl sulfoxide, Ringer's acetate, pH adjuster, etc. A serum-free medium or cell preservation solution can also be prepared.
本発明の組成物は，角膜内皮機能不全患者に投与される直前に調製して，調製後速やかに使用することが好ましいが，施術の都合等により速やかな移植が困難な場合には，例えば，96時間，72時間，48時間，24時間，12時間，又は数時間等，その状況に応じて4℃で保存することもできる。本発明の組成物の角膜内皮機能不全患者への投与は，この組成物に含まれるヒト角膜内皮細胞を遠心して沈殿させた後，薬学的に許容し得る塩，所望により薬学的に許容し得るALK-5阻害剤，Rhoキナーゼ阻害剤等を含有する水溶液に懸濁させ，これを注射器に移し，注射針を通じて眼球内に注入して行われる。このとき，Rhoキナーゼ阻害剤としてY27632を使用する場合，その最終濃度は好ましくは50〜150μMであり，より好ましくは最終濃度が100μMである。また，一つの眼球あたり注入されるヒト角膜内皮細胞の数は，１回に1×105〜8×105個である。なお，本発明において，ヒト角膜内皮細胞を移植するというときは，培養して増殖させた自家又は他家のヒト角膜内皮細胞を，ヒトの眼球内に投与することをいい，投与の一手法として注射器により前房内へ局所注入する方法が挙げられる。ヒト角膜内皮細胞を移植された患者は，移植後少なくとも3時間，うつむき姿勢を維持した状態に置かれる。 The composition of the present invention is preferably prepared immediately before being administered to a patient with corneal endothelial dysfunction, and is preferably used immediately after the preparation. It can be stored at 4 ° C depending on the situation, such as 96 hours, 72 hours, 48 hours, 24 hours, 12 hours, or several hours. Administration of the composition of the present invention to a patient with corneal endothelial dysfunction is performed by centrifuging and precipitating human corneal endothelial cells contained in the composition, and then pharmaceutically acceptable salts, and optionally pharmaceutically acceptable. Suspended in an aqueous solution containing an ALK-5 inhibitor, Rho kinase inhibitor, etc., transferred to a syringe, and injected into the eyeball through a syringe needle. At this time, when Y27632 is used as a Rho kinase inhibitor, the final concentration is preferably 50 to 150 μM, and more preferably the final concentration is 100 μM. The number of human corneal endothelial cells injected per eyeball is 1 × 10 5 to 8 × 10 5 at a time. In the present invention, when transplanting human corneal endothelial cells, it refers to administering autologous or cultivated human corneal endothelial cells cultured and proliferated into the human eyeball as one method of administration. A method of locally injecting into the anterior chamber with a syringe is mentioned. Patients who have been transplanted with human corneal endothelial cells are left in a depressed position for at least 3 hours after transplantation.
本発明の組成物が移植されるべき患者は，角膜内皮機能不全患者の中でも，特に，角膜上での角膜内皮細胞の密度が約500個／mm２以下となり，角膜内皮細胞のポンプ機能及びバリア機能の低下した患者であり，水疱性角膜症，角膜浮腫，角膜白斑，又は円錐角膜の患者である。かかる患者に本発明の組成物が投与されることにより，組成物に含まれるヒト角膜内皮細胞が角膜に定着するとともに増殖し，角膜上での角膜内皮細胞の密度が増加する。その結果，角膜内皮細胞のポンプ機能及びバリア機能が回復し，角膜内皮機能不全の諸症状が緩解され得る。 Among the patients with corneal endothelial dysfunction, the patient to be transplanted with the composition of the present invention has a corneal endothelial cell density of about 500 cells / mm 2 or less on the cornea, and the corneal endothelial cell pumping function and barrier Patients with impaired function, patients with bullous keratopathy, corneal edema, corneal vitiligo, or keratoconus. When the composition of the present invention is administered to such a patient, human corneal endothelial cells contained in the composition are fixed and proliferated in the cornea, and the density of corneal endothelial cells on the cornea is increased. As a result, the pumping function and barrier function of corneal endothelial cells are restored, and various symptoms of corneal endothelial dysfunction can be alleviated.
以下，実施例を参照して本発明を更に詳細に説明するが，本発明が実施例に限定されることは意図しない。 Hereinafter, the present invention will be described in more detail with reference to examples. However, it is not intended that the present invention be limited to the examples.
〔ヒト間葉系幹細胞の馴化培地（hMSC馴化培地）の作製〕
ヒト骨髄由来のヒト間葉系幹細胞を，5,000〜10,000 個/cm2の密度となるように150mm細胞培養用プレート（コーニング社製）に播種し，10％ FCS/DMEM培地を用いてサブコンフルエントになるまで培養した。細胞を，PBS(-)で2回洗浄した後，トリプシン処理して細胞を細胞培養用プレートから剥離し，次いで10％ FCS/DMEM培地を添加して懸濁した後，遠心（1200rpm，5分）して細胞を回収した。細胞を10％ FCS/DMEM培地で懸濁して，3,000〜5,000個/cm2の密度となるように150mm細胞培養用プレート（コーニング社製）に播種し，細胞密度がプレート底面に対し50〜70％になるまで培養した。培地を捨て，8％ FCS，200μg/mL CaCl2・2H2O，0.08％(w/v) コンドロイチン硫酸Cナトリウム（WAKO）及び50μg/mL ゲンタマイシンを添加したOpti-MEMTM I Reduced-Serum Medium, Liquid（Gibco社製）培地を40mL加えて，約16時間培養した。培養後，培地を回収して遠心（1500rpm，5分）し，得られた上清を0.2μmメンブランフィルターで濾過した。プレートに新しい培地を40mL加えて更に細胞を培養し，以後12〜24時間毎に培地の回収と新しい培地の添加を3〜5日間の間隔で繰り返して行った。回収した培地を遠心（1500rpm，5分）し，得られた上清を0.2μmメンブランフィルターで濾過した。濾過後の培地をヒト間葉系幹細胞の馴化培地（hMSC馴化培地）とした。hMSC馴化培地は，4℃又は凍結（-30℃）して保存し，4℃で保存する場合は，保存期限を10日間とした。このようにして調製したhMSC馴化培地は，以下に詳述するヒト角膜内皮細胞の初代培養及び継代培養において，ヒト角膜内皮細胞培養用基本培地に代えて，そのまま又は他の培地に添加して，ヒト角膜内皮細胞培養用の培地として使用することができる。
[Preparation of conditioned medium of human mesenchymal stem cells (hMSC conditioned medium)]
Human bone marrow-derived human mesenchymal stem cells are seeded on a 150 mm cell culture plate (Corning) at a density of 5,000 to 10,000 cells / cm 2 and subconfluent using 10% FCS / DMEM medium. Cultured until complete. The cells were washed twice with PBS (-), and treated with trypsin to detach the cells from the cell culture plate. Then, 10% FCS / DMEM medium was added and suspended, followed by centrifugation (1200 rpm, 5 minutes). And the cells were collected. Cells are suspended in 10% FCS / DMEM medium and seeded on a 150 mm cell culture plate (Corning) at a density of 3,000 to 5,000 cells / cm 2 , and the cell density is 50 to 70 relative to the bottom of the plate. Incubated until%. Discard the medium, Opti-MEM TM I Reduced-Serum Medium, supplemented with 8% FCS, 200 μg / mL CaCl 2 · 2H 2 O, 0.08% (w / v) chondroitin sulfate C sodium (WAKO) and 50 μg / mL gentamicin, 40 mL of Liquid (Gibco) medium was added and cultured for about 16 hours. After culturing, the medium was collected and centrifuged (1500 rpm, 5 minutes), and the resulting supernatant was filtered through a 0.2 μm membrane filter. 40 mL of a new medium was added to the plate and the cells were further cultured. Thereafter, the medium was collected and added every 12 to 24 hours at intervals of 3 to 5 days. The collected medium was centrifuged (1500 rpm, 5 minutes), and the resulting supernatant was filtered through a 0.2 μm membrane filter. The medium after filtration was used as a conditioned medium for human mesenchymal stem cells (hMSC conditioned medium). The hMSC conditioned medium was stored at 4 ° C or frozen (-30 ° C), and when stored at 4 ° C, the storage period was 10 days. The hMSC conditioned medium thus prepared is used as it is or in addition to other medium in the primary culture and subculture of human corneal endothelial cells described in detail below, instead of the basic medium for culturing human corneal endothelial cells. , It can be used as a medium for culturing human corneal endothelial cells.
〔ヒト角膜内皮細胞の初代培養〕
研究用ヒト角膜組織（シアトルアイバンク社製）から，鑷子を用いてヒト角膜内皮細胞を基底膜（デスメ膜）とともに剥離させた。剥離させたヒト角膜内皮細胞に，コラゲナーゼ溶液（コラゲナーゼを1mg/mLの濃度で添加したOpti-MEMTM I Reduced-Serum Medium）を添加して静置し，基底膜よりヒト角膜内皮細胞を剥離させた。次いで細胞を軽く振り混ぜて懸濁させ，これにヒト角膜内皮細胞培養用基本培地（8％ FCS，200μg/mL CaCl2・2H2O，0.08％(w/v) コンドロイチン硫酸Cナトリウム（WAKO）, 20μg/mL アスコルビン酸，50μg/mL ゲンタマイシン，5ng/mL EGF，1μM SB431542（TOCRIS社製）及び10μM Y27632（和光純薬工業）を添加したOpti-MEM I Reduced-Serum Medium, Liquid培地，以下「基本培地」）を添加して遠心（1200rpm，5分）し，細胞を回収した。細胞を，基本培地で懸濁し，細胞培養用プレート（コーニング社製）に，フラスコの底面の3分の1が細胞で占められる密度となるように播種し，37℃，5％CO2存在下で培養した。初代培養は，細胞がコンフルエントに達するまで行い，この間，培地を2日毎に交換した。
[Primary culture of human corneal endothelial cells]
Human corneal endothelial cells were detached from a research human corneal tissue (manufactured by Seattle Eye Bank) together with a basement membrane (Desme membrane) using an insulator. To the exfoliated human corneal endothelial cells, add a collagenase solution (Opti-MEM ™ I Reduced-Serum Medium supplemented with collagenase at a concentration of 1 mg / mL) and allow to stand to exfoliate the human corneal endothelial cells from the basement membrane. It was. Then, the cells are gently shaken to suspend, and then basal medium for human corneal endothelial cell culture (8% FCS, 200μg / mL CaCl 2 · 2H 2 O, 0.08% (w / v) chondroitin sulfate C sodium (WAKO) , 20 μg / mL ascorbic acid, 50 μg / mL gentamicin, 5 ng / mL EGF, 1 μM SB431542 (manufactured by TOCRIS) and 10 μM Y27632 (Wako Pure Chemical Industries), Opti-MEM I Reduced-Serum Medium, Liquid medium, hereinafter “ Basic medium ") was added and centrifuged (1200 rpm, 5 minutes), and the cells were collected. The cells are suspended in a basic medium, and seeded on a cell culture plate (Corning) so that the density is such that one-third of the bottom of the flask is occupied by the cells, at 37 ° C in the presence of 5% CO 2. In culture. Primary culture was performed until the cells reached confluence, during which the medium was changed every 2 days.
〔ヒト角膜内皮細胞の継代培養〕
上記初代培養で，コンフルエントになるまで培養したヒト角膜内皮細胞を，培地を除去してPBS(-)で２回洗浄した後，トリプシン処理して剥離した。基本培地を加えて細胞を懸濁させた後，遠心して細胞を回収した。細胞を，基本培地で懸濁させて，細胞培養用プレートに，プレート底面の約3分の1が細胞で占められるように播種し，コンフルエントになるまで培養した。この間，培地を2日毎に交換した。
[Subculture of human corneal endothelial cells]
Human corneal endothelial cells cultured in the primary culture until confluent were removed, washed twice with PBS (−), and then detached by trypsinization. After adding the basic medium to suspend the cells, the cells were collected by centrifugation. The cells were suspended in a basic medium, seeded on a cell culture plate so that about one third of the bottom of the plate was occupied by cells, and cultured until confluent. During this time, the medium was changed every 2 days.
〔ヒト角膜内皮細胞の細胞保存試液中での保存〕
細胞培養用プレートから培地を除去し，PBS(-)で細胞を1回洗浄した後，細胞培養用プレートにPBS(-)を添加し，5％CO２存在下，37℃で10分間，細胞を静置させた。PBS(-)を除去し，TrypLETM select 10×（Life Technologies）を添加し，5％CO２存在下，37℃で10分間，細胞を静置させた。次いで，PBS(-)を添加し，細胞が単一の細胞にまで分離するようにピペッティングしてから，細胞を遠沈管に回収した。遠心（1200 rpm，5分）して細胞を沈殿させて上清を除去し，次いで基本培地を添加して細胞を懸濁させ，その一部を分取して生細胞数を計測した。
[Preservation of human corneal endothelial cells in cell preservation solution]
After removing the medium from the cell culture plate and washing the cells once with PBS (-), PBS (-) was added to the cell culture plate and the cells were cultured at 37 ° C for 10 minutes in the presence of 5% CO 2. Was allowed to stand. PBS (−) was removed, TrypLE ™ select 10 × (Life Technologies) was added, and the cells were allowed to stand at 37 ° C. for 10 minutes in the presence of 5% CO 2 . Subsequently, PBS (-) was added and pipetting was performed so that the cells separated into single cells, and then the cells were collected in a centrifuge tube. The cells were precipitated by centrifugation (1200 rpm, 5 minutes), the supernatant was removed, then the basic medium was added to suspend the cells, a part of them was taken, and the number of viable cells was counted.
細胞を2×105個ずつ6本のチューブに分取し，遠心（1200 rpm，5分）して細胞を沈殿させて上清を除去した。各チューブに，(i)〜(vi))の6種類の細胞保存試液（(i)：セリオキープ，(ii)：25μg/mLのエピガロカテキンガレートを含有するセリオキープ，(iii)：10μM Y27632を含むOpti-MEM I Reduced-Serum Medium, Liquid，(iv)：25μg/mLのエピガロカテキンガレートを含有し，10μM Y27632を含むOpti-MEM I Reduced-Serum Medium, Liquid，(v)：オペガード（登録商標，千寿製薬株式会社），及び(vi)：25μg/mLのエピガロカテキンガレートを含有するオペガード）をそれぞれ添加して細胞を懸濁させた後，遠心（1200 rpm，5分）して細胞を沈殿させて上清を除去した。次いで，(i)〜(vi)の6種類の細胞保存試液を80μLずつ，対応する各チューブにそれぞれ添加し，細胞を懸濁させた。懸濁させた細胞を4℃で72時間静置した後，トリパンブルー染色により細胞の生存率を測定した。 Cells were sorted into 6 tubes each of 2 × 10 5 cells, centrifuged (1200 rpm, 5 minutes) to precipitate the cells, and the supernatant was removed. In each tube, six types of cell preservation solutions (i) to (vi) ((i): seriokeep, (ii): seriokeep containing 25 μg / mL epigallocatechin gallate, (iii): 10 μM Y27632) Opti-MEM I Reduced-Serum Medium, Liquid, (iv): Containing 25 μg / mL epigallocatechin gallate, and 10 μM Y27632 Opti-MEM I Reduced-Serum Medium, Liquid, (v): Opgard (registered) (Trademark, Senju Pharmaceutical Co., Ltd.), and (vi): Opegard containing 25 μg / mL epigallocatechin gallate) were added to suspend the cells, followed by centrifugation (1200 rpm, 5 minutes). And the supernatant was removed. Next, 80 μL of each of the six types of cell preservation reagents (i) to (vi) was added to each corresponding tube to suspend the cells. The suspended cells were allowed to stand at 4 ° C. for 72 hours, and then cell viability was measured by trypan blue staining.
〔各細胞保存試液中でのヒト角膜内皮細胞の生存率〕
上記6種類の細胞保存試液中で4℃で72時間静置した後のヒト角膜内皮細胞の生存率は，(i)：セリオキープで82.5％，(ii)：25μg/mLのエピガロカテキンガレートを含有するセリオキープで96.7％，(iii)：10μM Y27632を含むOpti-MEM I Reduced-Serum Medium, Liquidで5.1％，(iv)：25μg/mLのエピガロカテキンガレートと10μM Y27632とを含むOpti-MEMTM I Reduced-Serum Medium, Liquidで67.3％，(v)：オペガードで0％，及び(vi)：25μg/mLのエピガロカテキンガレートを含有するオペガードで23.7％，であった。以上の結果は，25μg/mLのエピガロカテキンガレートを含有するセリオキープが，懸濁状態のヒト角膜内皮細胞の死滅を防止するうえで最も効果的であることを示すものであり，(ii)のエピガロカテキンガレートを含有する溶液中にヒト角膜内皮細胞を含んでなる組成物が，(i)〜(vi)の中で，角膜内皮機能不全患者への移植用組成物として最も好適であることを示すものである。また，仮に移植用の細胞に求められる好適な細胞の生存率を95％以上と想定すると，(ii)の細胞保存試液中での72時間経過後の細胞の生存率が96.7％であることから，(ii)の細胞保存試液を用いて調製した組成物に含まれるヒト角膜内皮細胞は，調製後少なくとも72時間は，角膜内皮機能不全患者への移植用に使用できる。
[Viability of human corneal endothelial cells in each cell preservation solution]
The survival rate of human corneal endothelial cells after standing at 4 ° C for 72 hours in the above six cell preservation solutions was (i): 82.5% seriokeep, (ii): 25 μg / mL epigallocatechin gallate. Seriokeep containing 96.7%, (iii) Opti-MEM containing 10 μM Y27632 Opti-MEM I Reduced-Serum Medium, Liquid 5.1%, (iv): Opti-MEM containing 25 μg / mL epigallocatechin gallate and 10 μM Y27632 TM I Reduced-Serum Medium, Liquid (67.3%), (v): Opeguard 0%, and (vi): Opgard containing 25 μg / mL epigallocatechin gallate 23.7%. The above results indicate that seriokeep containing 25 μg / mL epigallocatechin gallate is most effective in preventing the death of suspended human corneal endothelial cells. A composition comprising human corneal endothelial cells in a solution containing epigallocatechin gallate is most suitable as a composition for transplantation to patients with corneal endothelial dysfunction among (i) to (vi). Is shown. Assuming that the suitable cell survival rate required for cells for transplantation is 95% or higher, the cell survival rate after 72 hours in the cell storage reagent of (ii) is 96.7%. The human corneal endothelial cells contained in the composition prepared using the cell preservation solution of (ii) can be used for transplantation to patients with corneal endothelial dysfunction for at least 72 hours after preparation.
本発明によれば，角膜内皮機能不全患者に移植するためにヒト角膜内皮細胞を調製する際の時間的制約が大幅に緩和されることから，より確実に医療現場に移植用のヒト角膜内皮細胞を供給することができる。
According to the present invention, the time constraint when preparing human corneal endothelial cells for transplantation to patients with corneal endothelial dysfunction is greatly eased, so that human corneal endothelial cells for transplantation in the medical field more reliably. Can be supplied.
Claims (13)
The composition according to claim 12, wherein the concentration of the chondroitin sulfate or a salt thereof is 0.08% (w / v).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015005492A JP6637656B2 (en) | 2014-01-16 | 2015-01-15 | Transplant composition containing corneal endothelial cells |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014018898 | 2014-01-16 | ||
| JP2014018898 | 2014-01-16 | ||
| JP2015005492A JP6637656B2 (en) | 2014-01-16 | 2015-01-15 | Transplant composition containing corneal endothelial cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019146371A Division JP2019217310A (en) | 2014-01-16 | 2019-08-08 | Composition for transplantation containing corneal endothelial cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015155400A true JP2015155400A (en) | 2015-08-27 |
| JP6637656B2 JP6637656B2 (en) | 2020-01-29 |
Family
ID=54774974
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015005492A Active JP6637656B2 (en) | 2014-01-16 | 2015-01-15 | Transplant composition containing corneal endothelial cells |
| JP2019146371A Withdrawn JP2019217310A (en) | 2014-01-16 | 2019-08-08 | Composition for transplantation containing corneal endothelial cell |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019146371A Withdrawn JP2019217310A (en) | 2014-01-16 | 2019-08-08 | Composition for transplantation containing corneal endothelial cell |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6637656B2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017183655A1 (en) * | 2016-04-20 | 2017-10-26 | 京都府公立大学法人 | Method for producing cultivated epithelial cell sheet |
| WO2019142833A1 (en) * | 2018-01-16 | 2019-07-25 | 学校法人慶應義塾 | METHOD FOR DERIVING CORNEAL ENDOTHELIUM REPLACEMENT CELLS FROM iPS CELLS |
| CN110179823A (en) * | 2019-06-18 | 2019-08-30 | 中国医学科学院生物医学工程研究所 | A kind of living cells delivery system and preparation method thereof based on the coordination of metal polyphenol |
| WO2020045642A1 (en) * | 2018-08-31 | 2020-03-05 | 学校法人同志社 | Composition and method for preserving or culturing ocular cells |
| WO2020071438A1 (en) * | 2018-10-02 | 2020-04-09 | 学校法人同志社 | Method and vessel for preserving corneal endothelial cells |
| JP2020054330A (en) * | 2018-10-02 | 2020-04-09 | 学校法人同志社 | Method and container for storing corneal endothelial cell |
| WO2022085680A1 (en) * | 2020-10-22 | 2022-04-28 | 京都府公立大学法人 | Preservation method of human corneal endothelial cells and/or human corneal endothelial progenitor cells |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014038639A1 (en) * | 2012-09-07 | 2014-03-13 | 日本ケミカルリサーチ株式会社 | Medium, for culturing corneal endothelial cells, containing conditioned medium from mesenchymal stem cells |
-
2015
- 2015-01-15 JP JP2015005492A patent/JP6637656B2/en active Active
-
2019
- 2019-08-08 JP JP2019146371A patent/JP2019217310A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014038639A1 (en) * | 2012-09-07 | 2014-03-13 | 日本ケミカルリサーチ株式会社 | Medium, for culturing corneal endothelial cells, containing conditioned medium from mesenchymal stem cells |
Non-Patent Citations (7)
| Title |
|---|
| BIO INDUSTRY, vol. 24, no. 1, JPN6018046056, 2007, pages 64 - 71, ISSN: 0004026604 * |
| JOYCE, N.C., ET AL., CORNEA, vol. 23(Suppl.1), JPN6013048221, 2004, pages 8 - 19, ISSN: 0004026601 * |
| LU, X., ET AL., MOLECULAR VISION, vol. 16, JPN6013048212, 2010, pages 611 - 622, ISSN: 0004026599 * |
| PEH, G.S.L., ET AL., TRANSPLANTATION, vol. 91(8), JPN6013048218, 2011, pages 811 - 819, ISSN: 0004026600 * |
| PLOS ONE, vol. Vol. 8, No. 7, e69009, JPN6018046054, 2013, pages 1 - 10, ISSN: 0004026603 * |
| 小泉範子: "体性幹細胞を用いた角膜内皮再生医療の開発", 医学のあゆみ, vol. 241(10), JPN6013048223, 9 June 2012 (2012-06-09), pages 765 - 770, ISSN: 0004026602 * |
| 立石 義雄: "生体組織及び臓器の新規保存液開発に関する研究開発", 平成１４年度 課題対応技術革新促進事業 課題対応新技術研究開発事業 成果報告書, JPN6018046058, 2004, pages 82 - 85, ISSN: 0003925384 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017183655A1 (en) * | 2016-04-20 | 2017-10-26 | 京都府公立大学法人 | Method for producing cultivated epithelial cell sheet |
| JPWO2017183655A1 (en) * | 2016-04-20 | 2019-02-21 | 京都府公立大学法人 | Method for producing cultured epithelial sheet |
| US11479754B2 (en) | 2016-04-20 | 2022-10-25 | Kyoto Prefectural Public University Corporation | Method for producing cultivated epithelial cell sheet |
| JP7024974B2 (en) | 2016-04-20 | 2022-02-24 | 京都府公立大学法人 | Method for manufacturing cultured epithelial sheet |
| WO2019142833A1 (en) * | 2018-01-16 | 2019-07-25 | 学校法人慶應義塾 | METHOD FOR DERIVING CORNEAL ENDOTHELIUM REPLACEMENT CELLS FROM iPS CELLS |
| JPWO2020045642A1 (en) * | 2018-08-31 | 2021-08-12 | 学校法人同志社 | Compositions and Methods for Preserving or Culturing Eye Cells |
| CN113056556A (en) * | 2018-08-31 | 2021-06-29 | 学校法人同志社 | Compositions and methods for preserving or culturing ocular cells |
| WO2020045642A1 (en) * | 2018-08-31 | 2020-03-05 | 学校法人同志社 | Composition and method for preserving or culturing ocular cells |
| JP2020054330A (en) * | 2018-10-02 | 2020-04-09 | 学校法人同志社 | Method and container for storing corneal endothelial cell |
| WO2020071438A1 (en) * | 2018-10-02 | 2020-04-09 | 学校法人同志社 | Method and vessel for preserving corneal endothelial cells |
| US11445723B2 (en) | 2018-10-02 | 2022-09-20 | The Doshisha | Method and container for preserving corneal endothelial cells |
| CN110179823A (en) * | 2019-06-18 | 2019-08-30 | 中国医学科学院生物医学工程研究所 | A kind of living cells delivery system and preparation method thereof based on the coordination of metal polyphenol |
| WO2022085680A1 (en) * | 2020-10-22 | 2022-04-28 | 京都府公立大学法人 | Preservation method of human corneal endothelial cells and/or human corneal endothelial progenitor cells |
| JPWO2022085680A1 (en) * | 2020-10-22 | 2022-04-28 | ||
| CN116583593A (en) * | 2020-10-22 | 2023-08-11 | 京都府公立大学法人 | Preservation method of human corneal endothelial cells and/or human corneal endothelial precursor cells |
| JP7361431B2 (en) | 2020-10-22 | 2023-10-16 | 京都府公立大学法人 | Method for preserving human corneal endothelial cells and/or human corneal endothelial progenitor cells |
| US20230380417A1 (en) * | 2020-10-22 | 2023-11-30 | Kyoto Prefectural Public University Corporation | A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6637656B2 (en) | 2020-01-29 |
| JP2019217310A (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6637656B2 (en) | Transplant composition containing corneal endothelial cells | |
| JP6286353B2 (en) | Culture medium for corneal endothelial cell culture containing conditioned medium of mesenchymal stem cells | |
| EP2733201B1 (en) | Method for preparing corneal endothelial cell | |
| EP2975117B1 (en) | Method for producing human corneal epithelium sheet | |
| Notara et al. | IL6 and the human limbal stem cell niche: A mediator of epithelial–stromal interaction | |
| WO2012117333A1 (en) | Isolation and expansion of adult stem cells, their therapeutic composition and uses thereof | |
| KR20170020527A (en) | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof | |
| JP7220482B2 (en) | Compositions and methods for intestinal organoid culture | |
| AU2011208948B2 (en) | Method for stem cell differentiation | |
| WO2016127259A1 (en) | Alveolar-like macrophages and method of generating same | |
| KR20160131096A (en) | Method for generating endothelial colony forming cell-like cells | |
| Parekh et al. | Reconstruction and regeneration of corneal endothelium: a review on current methods and future aspects | |
| CN112538458A (en) | Method for reprogramming cells | |
| EP2415862B1 (en) | Method for inducing cell death in pluripotent stem cells and differentiated cells other than cardiac myocytes | |
| CN107312745B (en) | Serum-free epithelial cell culture solution | |
| KR101895648B1 (en) | Pharmaceutical composition for treatment of neurological diseases comprsing dental pulp stem cell and method for preparing the same | |
| KR20210153066A (en) | Methods for culturing cell populations and their use | |
| US20190161737A1 (en) | Process for continuous cell culture of cancer cells and cancer stem cells | |
| WO2016129654A1 (en) | Method for preparing corneal endothelial precursor cells | |
| KR20230124247A (en) | Method of endotheliocyte isolation and culture in cornea using endothelial cell-specific ECM-modulated culture condition | |
| Jouppila | Optimizing differentiation of human pluripotent stem cells towards corneal epithelium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20150209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150209 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160706 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180129 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20180129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190124 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190808 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190913 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191024 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191202 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191223 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6637656 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |